Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 248

1.

PARP1 trapping by PARP inhibitors drives cytotoxicity both in cancer cells and healthy bone marrow.

Hopkins TA, Ainsworth WB, Ellis PA, Donawho CK, DiGiammarino EL, Panchal SC, Abraham VC, Algire MA, Shi Y, Olson AM, Johnson EF, Wilsbacher JL, Maag D.

Mol Cancer Res. 2018 Nov 14. pii: molcanres.0138.2018. doi: 10.1158/1541-7786.MCR-18-0138. [Epub ahead of print]

PMID:
30429212
2.

Noncovalent interactions dominate dynamic heme distortion in cytochrome P450 4B1.

Jennings GK, Hsu MH, Shock LS, Johnson EF, Hackett JC.

J Biol Chem. 2018 Jul 20;293(29):11433-11446. doi: 10.1074/jbc.RA118.004044. Epub 2018 Jun 1.

PMID:
29858244
3.

Alpha-1 antitrypsin deficiency panniculitis: clinical and pathologic characteristics of 10 cases.

Johnson EF, Tolkachjov SN, Gibson LE.

Int J Dermatol. 2018 Aug;57(8):952-958. doi: 10.1111/ijd.14012. Epub 2018 Apr 29.

PMID:
29707779
4.
5.

The X-Ray Crystal Structure of the Human Mono-Oxygenase Cytochrome P450 3A5-Ritonavir Complex Reveals Active Site Differences between P450s 3A4 and 3A5.

Hsu MH, Savas U, Johnson EF.

Mol Pharmacol. 2018 Jan;93(1):14-24. doi: 10.1124/mol.117.109744. Epub 2017 Nov 1.

PMID:
29093019
6.

Determinants of the Inhibition of DprE1 and CYP2C9 by Antitubercular Thiophenes.

Liu R, Lyu X, Batt SM, Hsu MH, Harbut MB, Vilchèze C, Cheng B, Ajayi K, Yang B, Yang Y, Guo H, Lin C, Gan F, Wang C, Franzblau SG, Jacobs WR Jr, Besra GS, Johnson EF, Petrassi M, Chatterjee AK, Fütterer K, Wang F.

Angew Chem Int Ed Engl. 2017 Oct 9;56(42):13011-13015. doi: 10.1002/anie.201707324. Epub 2017 Sep 7.

7.

Heme-thiolate sulfenylation of human cytochrome P450 4A11 functions as a redox switch for catalytic inhibition.

Albertolle ME, Kim D, Nagy LD, Yun CH, Pozzi A, Savas Ü, Johnson EF, Guengerich FP.

J Biol Chem. 2017 Jul 7;292(27):11230-11242. doi: 10.1074/jbc.M117.792200. Epub 2017 May 22.

8.

Permanent Draft Genome Sequence of Desulfurococcus amylolyticus Strain Z-533T, a Peptide and Starch Degrader Isolated from Thermal Springs in the Kamchatka Peninsula and Kunashir Island, Russia.

Susanti D, Johnson EF, Lapidus A, Han J, Reddy TB, Mukherjee S, Pillay M, Perevalova AA, Ivanova NN, Woyke T, Kyrpides NC, Mukhopadhyay B.

Genome Announc. 2017 Apr 13;5(15). pii: e00078-17. doi: 10.1128/genomeA.00078-17.

9.

The Crystal Structure of Cytochrome P450 4B1 (CYP4B1) Monooxygenase Complexed with Octane Discloses Several Structural Adaptations for ω-Hydroxylation.

Hsu MH, Baer BR, Rettie AE, Johnson EF.

J Biol Chem. 2017 Mar 31;292(13):5610-5621. doi: 10.1074/jbc.M117.775494. Epub 2017 Feb 6.

10.

Aminomethyl-Derived Beta Secretase (BACE1) Inhibitors: Engaging Gly230 without an Anilide Functionality.

Butler CR, Ogilvie K, Martinez-Alsina L, Barreiro G, Beck EM, Nolan CE, Atchison K, Benvenuti E, Buzon L, Doran S, Gonzales C, Helal CJ, Hou X, Hsu MH, Johnson EF, Lapham K, Lanyon L, Parris K, O'Neill BT, Riddell D, Robshaw A, Vajdos F, Brodney MA.

J Med Chem. 2017 Jan 12;60(1):386-402. doi: 10.1021/acs.jmedchem.6b01451. Epub 2016 Dec 20.

11.

A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale.

Isakoff SJ, Puhalla S, Domchek SM, Friedlander M, Kaufman B, Robson M, Telli ML, Diéras V, Han HS, Garber JE, Johnson EF, Maag D, Qin Q, Giranda VL, Shepherd SP.

Future Oncol. 2017 Feb;13(4):307-320. doi: 10.2217/fon-2016-0412. Epub 2016 Oct 14.

12.

Leukocytoclastic vasculitis in children: clinical characteristics, subtypes, causes and direct immunofluorescence findings of 56 biopsy-confirmed cases.

Johnson EF, Wetter DA, Lehman JS, Hand JL, Davis DM, Tollefson MM.

J Eur Acad Dermatol Venereol. 2017 Mar;31(3):544-549. doi: 10.1111/jdv.13952. Epub 2016 Sep 19.

PMID:
27580419
13.
15.

Permanent draft genome sequence of Desulfurococcus mobilis type strain DSM 2161, a thermoacidophilic sulfur-reducing crenarchaeon isolated from acidic hot springs of Hveravellir, Iceland.

Susanti D, Johnson EF, Lapidus A, Han J, Reddy TB, Pilay M, Ivanova NN, Markowitz VM, Woyke T, Kyrpides NC, Mukhopadhyay B.

Stand Genomic Sci. 2016 Jan 13;11:3. doi: 10.1186/s40793-015-0128-4. eCollection 2016.

16.

Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors.

Hopkins TA, Shi Y, Rodriguez LE, Solomon LR, Donawho CK, DiGiammarino EL, Panchal SC, Wilsbacher JL, Gao W, Olson AM, Stolarik DF, Osterling DJ, Johnson EF, Maag D.

Mol Cancer Res. 2015 Nov;13(11):1465-77. doi: 10.1158/1541-7786.MCR-15-0191-T. Epub 2015 Jul 27.

17.

Utilizing structures of CYP2D6 and BACE1 complexes to reduce risk of drug-drug interactions with a novel series of centrally efficacious BACE1 inhibitors.

Brodney MA, Beck EM, Butler CR, Barreiro G, Johnson EF, Riddell D, Parris K, Nolan CE, Fan Y, Atchison K, Gonzales C, Robshaw AE, Doran SD, Bundesmann MW, Buzon L, Dutra J, Henegar K, LaChapelle E, Hou X, Rogers BN, Pandit J, Lira R, Martinez-Alsina L, Mikochik P, Murray JC, Ogilvie K, Price L, Sakya SM, Yu A, Zhang Y, O'Neill BT.

J Med Chem. 2015 Apr 9;58(7):3223-52. doi: 10.1021/acs.jmedchem.5b00191. Epub 2015 Apr 1.

18.

Recurrent Oral and Genital Ulcers in an Infant: Neonatal Presentation of Pediatric Behçet Disease.

Johnson EF, Hawkins DM, Gifford LK, Smidt AC.

Pediatr Dermatol. 2015 Sep-Oct;32(5):714-7. doi: 10.1111/pde.12512. Epub 2015 Jan 30.

PMID:
25639516
19.

Pyrimidine-based tricyclic molecules as potent and orally efficacious inhibitors of wee1 kinase.

Tong Y, Torrent M, Florjancic AS, Bromberg KD, Buchanan FG, Ferguson DC, Johnson EF, Lasko LM, Maag D, Merta PJ, Olson AM, Osterling DJ, Soni N, Shoemaker AR, Penning TD.

ACS Med Chem Lett. 2014 Aug 6;6(1):58-62. doi: 10.1021/ml5002745. eCollection 2015 Jan 8.

20.

Contributions of ionic interactions and protein dynamics to cytochrome P450 2D6 (CYP2D6) substrate and inhibitor binding.

Wang A, Stout CD, Zhang Q, Johnson EF.

J Biol Chem. 2015 Feb 20;290(8):5092-104. doi: 10.1074/jbc.M114.627661. Epub 2015 Jan 1.

21.

Henoch-Schönlein purpura and systemic disease in children: retrospective study of clinical findings, histopathology and direct immunofluorescence in 34 paediatric patients.

Johnson EF, Lehman JS, Wetter DA, Lohse CM, Tollefson MM.

Br J Dermatol. 2015;172(5):1358-63. doi: 10.1111/bjd.13472. Epub 2015 Feb 25.

PMID:
25308217
22.

Areolar dermal nodule: challenge.

Berry RS, Johnson EF, Smidt AC.

Am J Dermatopathol. 2014 Sep;36(9):744-5. doi: 10.1097/DAD.0000000000000091. No abstract available.

PMID:
25147986
23.

Annular vesiculobullous eruption in a healthy young man.

Johnson EF, Jacobs MH, Smidt AC.

JAMA. 2013 Dec 18;310(23):2559-60. doi: 10.1001/jama.2013.283530. No abstract available.

PMID:
24346992
24.

Narcotic administration and fall-related injury in the hospital: implications for patient safety programs and providers.

Pierce JR Jr, Shirley M, Johnson EF, Kang H.

Int J Risk Saf Med. 2013;25(4):229-34. doi: 10.3233/JRS-130603.

PMID:
24305561
25.

Correlating structure and function of drug-metabolizing enzymes: progress and ongoing challenges.

Johnson EF, Connick JP, Reed JR, Backes WL, Desai MC, Xu L, Estrada DF, Laurence JS, Scott EE.

Drug Metab Dispos. 2014 Jan;42(1):9-22. doi: 10.1124/dmd.113.054627. Epub 2013 Oct 15. Review.

26.

Not just a diaper rash: LUMBAR syndrome.

Johnson EF, Smidt AC.

J Pediatr. 2014 Jan;164(1):208-9. doi: 10.1016/j.jpeds.2013.08.045. Epub 2013 Oct 7. No abstract available.

PMID:
24112868
27.

Picture of the month. Allergic contact dermatitis to nickel-containing dental work.

Johnson EF, Lau EG, Smidt AC.

JAMA Pediatr. 2013 Jun;167(6):581-2. doi: 10.1001/jamapediatrics.2013.328a. No abstract available.

PMID:
23733221
28.

Structural diversity of eukaryotic membrane cytochrome p450s.

Johnson EF, Stout CD.

J Biol Chem. 2013 Jun 14;288(24):17082-90. doi: 10.1074/jbc.R113.452805. Epub 2013 Apr 30. Review.

29.

Azaindole-Based Inhibitors of Cdc7 Kinase: Impact of the Pre-DFG Residue, Val 195.

Tong Y, Stewart KD, Florjancic AS, Harlan JE, Merta PJ, Przytulinska M, Soni N, Swinger KK, Zhu H, Johnson EF, Shoemaker AR, Penning TD.

ACS Med Chem Lett. 2013 Jan 15;4(2):211-5. doi: 10.1021/ml300348c. eCollection 2013 Feb 14.

30.

Structural characterization of human cytochrome P450 2C19: active site differences between P450s 2C8, 2C9, and 2C19.

Reynald RL, Sansen S, Stout CD, Johnson EF.

J Biol Chem. 2012 Dec 28;287(53):44581-91. doi: 10.1074/jbc.M112.424895. Epub 2012 Nov 1.

31.

Hit to Lead optimization of a novel class of squarate-containing polo-like kinases inhibitors.

Zhang Q, Xia Z, Mitten MJ, Lasko LM, Klinghofer V, Bouska J, Johnson EF, Penning TD, Luo Y, Giranda VL, Shoemaker AR, Stewart KD, Djuric SW, Vasudevan A.

Bioorg Med Chem Lett. 2012 Dec 15;22(24):7615-22. doi: 10.1016/j.bmcl.2012.10.009. Epub 2012 Oct 11.

PMID:
23103095
32.

Complete genome sequence of Desulfurococcus fermentans, a hyperthermophilic cellulolytic crenarchaeon isolated from a freshwater hot spring in Kamchatka, Russia.

Susanti D, Johnson EF, Rodriguez JR, Anderson I, Perevalova AA, Kyrpides N, Lucas S, Han J, Lapidus A, Cheng JF, Goodwin L, Pitluck S, Mavrommatis K, Peters L, Land ML, Hauser L, Gopalan V, Chan PP, Lowe TM, Atomi H, Bonch-Osmolovskaya EA, Woyke T, Mukhopadhyay B.

J Bacteriol. 2012 Oct;194(20):5703-4.

33.

Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase families.

Glaser KB, Li J, Marcotte PA, Magoc TJ, Guo J, Reuter DR, Tapang P, Wei RQ, Pease LJ, Bui MH, Chen Z, Frey RR, Johnson EF, Osterling DJ, Olson AM, Bouska JJ, Luo Y, Curtin ML, Donawho CK, Michaelides MR, Tse C, Davidsen SK, Albert DH.

J Pharmacol Exp Ther. 2012 Dec;343(3):617-27. doi: 10.1124/jpet.112.197087. Epub 2012 Aug 30.

34.

Discovery and SAR of orally efficacious tetrahydropyridopyridazinone PARP inhibitors for the treatment of cancer.

Zhu GD, Gong J, Gandhi VB, Liu X, Shi Y, Johnson EF, Donawho CK, Ellis PA, Bouska JJ, Osterling DJ, Olson AM, Park C, Luo Y, Shoemaker A, Giranda VL, Penning TD.

Bioorg Med Chem. 2012 Aug 1;20(15):4635-45. doi: 10.1016/j.bmc.2012.06.021. Epub 2012 Jun 19.

PMID:
22766219
35.

Aminopyrimidinone cdc7 kinase inhibitors.

Woods KW, Lai C, Miyashiro JM, Tong Y, Florjancic AS, Han EK, Soni N, Shi Y, Lasko L, Leverson JD, Johnson EF, Shoemaker AR, Penning TD.

Bioorg Med Chem Lett. 2012 Mar 1;22(5):1940-3. doi: 10.1016/j.bmcl.2012.01.041. Epub 2012 Jan 25.

PMID:
22326396
36.

Crystal structure of human cytochrome P450 2D6 with prinomastat bound.

Wang A, Savas U, Hsu MH, Stout CD, Johnson EF.

J Biol Chem. 2012 Mar 30;287(14):10834-43. doi: 10.1074/jbc.M111.307918. Epub 2012 Feb 3.

37.

Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor.

Liu X, Shi Y, Maag DX, Palma JP, Patterson MJ, Ellis PA, Surber BW, Ready DB, Soni NB, Ladror US, Xu AJ, Iyer R, Harlan JE, Solomon LR, Donawho CK, Penning TD, Johnson EF, Shoemaker AR.

Clin Cancer Res. 2012 Jan 15;18(2):510-23. doi: 10.1158/1078-0432.CCR-11-1973. Epub 2011 Nov 29.

38.

1-Benzyl-3-cetyl-2-methylimidazolium iodide (NH125) induces phosphorylation of eukaryotic elongation factor-2 (eEF2): a cautionary note on the anticancer mechanism of an eEF2 kinase inhibitor.

Chen Z, Gopalakrishnan SM, Bui MH, Soni NB, Warrior U, Johnson EF, Donnelly JB, Glaser KB.

J Biol Chem. 2011 Dec 23;286(51):43951-8. doi: 10.1074/jbc.M111.301291. Epub 2011 Oct 21.

40.

Ubiquitin-specific cysteine protease 2a (USP2a) regulates the stability of Aurora-A.

Shi Y, Solomon LR, Pereda-Lopez A, Giranda VL, Luo Y, Johnson EF, Shoemaker AR, Leverson J, Liu X.

J Biol Chem. 2011 Nov 11;286(45):38960-8. doi: 10.1074/jbc.M111.231498. Epub 2011 Sep 2.

41.

Navigating the kinome.

Metz JT, Johnson EF, Soni NB, Merta PJ, Kifle L, Hajduk PJ.

Nat Chem Biol. 2011 Apr;7(4):200-2. doi: 10.1038/nchembio.530. Epub 2011 Feb 20.

PMID:
21336281
42.

Scaffold oriented synthesis. Part 4: design, synthesis and biological evaluation of novel 5-substituted indazoles as potent and selective kinase inhibitors employing heterocycle forming and multicomponent reactions.

Akritopoulou-Zanze I, Wakefield BD, Gasiecki A, Kalvin D, Johnson EF, Kovar P, Djuric SW.

Bioorg Med Chem Lett. 2011 Mar 1;21(5):1480-3. doi: 10.1016/j.bmcl.2011.01.001. Epub 2011 Jan 11.

PMID:
21288717
43.

Scaffold oriented synthesis. Part 3: design, synthesis and biological evaluation of novel 5-substituted indazoles as potent and selective kinase inhibitors employing [2+3] cycloadditions.

Akritopoulou-Zanze I, Wakefield BD, Gasiecki A, Kalvin D, Johnson EF, Kovar P, Djuric SW.

Bioorg Med Chem Lett. 2011 Mar 1;21(5):1476-9. doi: 10.1016/j.bmcl.2011.01.007. Epub 2011 Jan 11.

PMID:
21282054
44.

Genistein, resveratrol, and 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside induce cytochrome P450 4F2 expression through an AMP-activated protein kinase-dependent pathway.

Hsu MH, Savas U, Lasker JM, Johnson EF.

J Pharmacol Exp Ther. 2011 Apr;337(1):125-36. doi: 10.1124/jpet.110.175851. Epub 2011 Jan 4.

45.

Structural characterization of the complex between alpha-naphthoflavone and human cytochrome P450 1B1.

Wang A, Savas U, Stout CD, Johnson EF.

J Biol Chem. 2011 Feb 18;286(7):5736-43. doi: 10.1074/jbc.M110.204420. Epub 2010 Dec 8.

46.

Substituted 4-amino-1H-pyrazolo[3,4-d]pyrimidines as multi-targeted inhibitors of insulin-like growth factor-1 receptor (IGF1R) and members of ErbB-family receptor kinases.

Wang GT, Mantei RA, Hubbard RD, Wilsbacher JL, Zhang Q, Tucker L, Hu X, Kovar P, Johnson EF, Osterling DJ, Bouska J, Wang J, Davidsen SK, Bell RL, Sheppard GS.

Bioorg Med Chem Lett. 2010 Oct 15;20(20):6067-71. doi: 10.1016/j.bmcl.2010.08.052. Epub 2010 Aug 13.

PMID:
20817523
47.

CYP2C8 exists as a dimer in natural membranes.

Hu G, Johnson EF, Kemper B.

Drug Metab Dispos. 2010 Nov;38(11):1976-83. doi: 10.1124/dmd.110.034942. Epub 2010 Aug 10.

48.

Imidazo[2,1-b]thiazoles: multitargeted inhibitors of both the insulin-like growth factor receptor and members of the epidermal growth factor family of receptor tyrosine kinases.

Fidanze SD, Erickson SA, Wang GT, Mantei R, Clark RF, Sorensen BK, Bamaung NY, Kovar P, Johnson EF, Swinger KK, Stewart KD, Zhang Q, Tucker LA, Pappano WN, Wilsbacher JL, Wang J, Sheppard GS, Bell RL, Davidsen SK, Hubbard RD.

Bioorg Med Chem Lett. 2010 Apr 15;20(8):2452-5. doi: 10.1016/j.bmcl.2010.03.015. Epub 2010 Mar 7.

PMID:
20346655
49.

Optimization of phenyl-substituted benzimidazole carboxamide poly(ADP-ribose) polymerase inhibitors: identification of (S)-2-(2-fluoro-4-(pyrrolidin-2-yl)phenyl)-1H-benzimidazole-4-carboxamide (A-966492), a highly potent and efficacious inhibitor.

Penning TD, Zhu GD, Gong J, Thomas S, Gandhi VB, Liu X, Shi Y, Klinghofer V, Johnson EF, Park CH, Fry EH, Donawho CK, Frost DJ, Buchanan FG, Bukofzer GT, Rodriguez LE, Bontcheva-Diaz V, Bouska JJ, Osterling DJ, Olson AM, Marsh KC, Luo Y, Giranda VL.

J Med Chem. 2010 Apr 22;53(8):3142-53. doi: 10.1021/jm901775y.

PMID:
20337371
50.

Discovery and SAR of substituted 3-oxoisoindoline-4-carboxamides as potent inhibitors of poly(ADP-ribose) polymerase (PARP) for the treatment of cancer.

Gandhi VB, Luo Y, Liu X, Shi Y, Klinghofer V, Johnson EF, Park C, Giranda VL, Penning TD, Zhu GD.

Bioorg Med Chem Lett. 2010 Feb 1;20(3):1023-6. doi: 10.1016/j.bmcl.2009.12.042. Epub 2009 Dec 14.

PMID:
20045315

Supplemental Content

Loading ...
Support Center